Data Insights

Zimberelimab by Arcus Biosciences for Hepatocellular Carcinoma: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Hepatocellular Carcinoma

Data Insights

Zimberelimab by Arcus Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Glioblastoma Multiforme (GBM)

Data Insights

Zimberelimab by Arcus Biosciences for Gallbladder Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Gallbladder Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Rectal Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Rectal Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Esophageal Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Esophageal Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Zimberelimab by Arcus Biosciences for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Extrahepatic Bile Duct Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Metastatic Colorectal Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

Zimberelimab by Arcus Biosciences for Gastric Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Gastric Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase III for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Non-Small Cell Lung Cancer

Data Insights

Zimberelimab by Arcus Biosciences for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Squamous Non-Small Cell Lung Cancer